CryoPort (NASDAQ:CYRX) vs. Azenta (NASDAQ:AZTA) Critical Contrast

Azenta (NASDAQ:AZTA) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Risk & Volatility

Azenta has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Azenta and CryoPort, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1	2	4	0	2.43
CryoPort	0	2	8	0	2.80

Azenta presently has a consensus price target of $41.20, suggesting a potential upside of 5.48%. CryoPort has a consensus price target of $19.33, suggesting a potential upside of 11.82%. Given CryoPort’s stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than Azenta.

Profitability

This table compares Azenta and CryoPort’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
CryoPort	-20.05%	-7.20%	-4.30%

Earnings & Valuation

This table compares Azenta and CryoPort”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$613.81 million	2.79	-$55.76 million	($2.76)	-14.15
CryoPort	$176.18 million	4.97	$78.30 million	($0.90)	-19.21

CryoPort has lower revenue, but higher earnings than Azenta. CryoPort is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

99.1% of Azenta shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CryoPort beats Azenta on 8 of the 14 factors compared between the two stocks.

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.